Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US6491916B1 · kind B1 · utility
68Cited by
12References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 9, 1998 |
| Grant date | Dec 10, 2002 |
| Priority date | — |
| Expiry date | Oct 9, 2018 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/867
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The binding specificity of the murine OKT3 has been transferred into a human antibody framework in order to reduce its immunogenicity. These “humanized” anti-CD3 monoclonal antibodies retain, in vitro, all the properties of native anti-CD3 antibodies, including T cell activation which has been correlated, in vivo, with the severe side-effects observed in transplant recipients after the first administration of the mAb.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.